ウパダシチニブ単剤治療は関節リウマチにおける患者報告アウトカムを改善する: SELECT-EARLY 試験および SELECT-MONOTHERAPY 試験結果

Rheumatology (Oxford). 2021;60(7):3209–21

Upadacitinib treatment results in statistically significant and clinically meaningful improvements in health-related quality of life.Strand, et al. evaluated the effect of upadacitinib monotherapy versus methotrexate (MTX) on patient-reported outcomes (PRO) in MTX-naïve and MTX-inadequate responder patients with moderately-to-severely active RA. Their research from the SELECT-EARLY and SELECT-MONOTHERAPY randomised controlled trials found that upadacitinib monotherapy resulted in clinically meaningful improvements in PROs, with significant improvements being seen as early as 2 weeks.

Keywords:


Publication thumbnail: ウパダシチニブ単剤治療は関節リウマチにおける患者報告アウトカムを改善する: SELECT-EARLY 試験および SELECT-MONOTHERAPY 試験結果
LinkedIn